Language:

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

The New England journal of medicine, 2018-11, Vol.379 (19), p.1811-1822 [Peer Reviewed Journal]

Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1805762 ;PMID: 30403938

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
Author: Dimopoulos, Meletios A ; Dytfeld, Dominik ; Grosicki, Sebastian ; Moreau, Philippe ; Takezako, Naoki ; Hori, Mitsuo ; Leleu, Xavier ; LeBlanc, Richard ; Suzuki, Kenshi ; Raab, Marc S ; Richardson, Paul G ; Popa McKiver, Mihaela ; Jou, Ying-Ming ; Shelat, Suresh G ; Robbins, Michael ; Rafferty, Brian ; San-Miguel, Jesús
Subjects: Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antibodies, Monoclonal, Humanized - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Chemotherapy ; Clinical trials ; Development and progression ; Dexamethasone ; Dexamethasone - administration & dosage ; Dexamethasone - adverse effects ; Disease-Free Survival ; Drug dosages ; Drug therapy ; Evidence-based medicine ; Female ; Humans ; Hyperglycemia ; Immunologic Factors - administration & dosage ; Immunologic Factors - adverse effects ; Immunomodulation ; Immunostimulation ; Immunotherapy ; Infection - chemically induced ; Male ; Medical prognosis ; Middle Aged ; Monoclonal antibodies ; Multiple myeloma ; Multiple Myeloma - drug therapy ; Multiple Myeloma - mortality ; Neutropenia ; Neutropenia - chemically induced ; Patients ; Proteasome inhibitors ; Response rates ; Steroids ; Survival ; Targeted cancer therapy ; Thalidomide - administration & dosage ; Thalidomide - adverse effects ; Thalidomide - analogs & derivatives
Is Part Of: The New England journal of medicine, 2018-11, Vol.379 (19), p.1811-1822
Description: In a randomized trial of pomalidomide plus dexamethasone with or without the immunostimulatory monoclonal antibody elotuzumab, the addition of elotuzumab doubled both the response rate and the duration of progression-free survival without increased toxic effects.
Publisher: United States: Massachusetts Medical Society
Language: English
Identifier: ISSN: 0028-4793
EISSN: 1533-4406
DOI: 10.1056/NEJMoa1805762
PMID: 30403938
Source: ProQuest One Psychology
MEDLINE
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1805762 ;PMID: 30403938

Searching Remote Databases, Please Wait